A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data Michael R. McClungClaude-Laurent BenhamouZulema Man • Witold TlustochowiczJose R. ZanchettaRachelle EusebioAna M. Balske • Ellen MatzkinWojciech P. OlszynskiRobert ReckerPierre D. Delmas

Michael R. McClung(Bone Health and Osteoporosis Foundation), José Zanchetta(Universidad del Salvador), Witold Tłustochowicz(Wojskowy Instytut Medycyny Lotniczej), Klinika Chorób
Unknown
January 1, 2013
Cited by 0

Related Papers

Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k
Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial
|Journal of Bone and Mineral Research|2008|508
Effects of teriparatide versus alendronate for treating glucocorticoid‐induced osteoporosis: Thirty‐six–month results of a randomized, double‐blind, controlled trial
|Arthritis & Rheumatism|2009|497